Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × urelumab × Dermatologic × Clear all

Phase

Status

Withdrawn 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 2 Lymphoid 2 Sarcoma 1 Plasma cell 1 Head & Neck 1 Gastrointestinal 1 Dermatologic 1 CNS 1

Conditions

Interventions

Ipilimumab 108 pembrolizumab 88 Nivolumab 87 aldesleukin 84 Cyclophosphamide 76 fludarabine phosphate 56 Interleukin-2 51 Dacarbazine 51 3-ingenyl angelate 41 Imiquimod 37 Vemurafenib 35 trametinib 34 Temozolomide 34 incomplete Freund's adjuvant 33 sargramostim 32 Peripheral Blood Stem Cell Transplantation 29 Radiotherapy 28 fludarabine 27 dabrafenib 27 Aminolevulinic Acid 27 Bevacizumab 26 Carboplatin 25 Photochemotherapy 24 Paclitaxel 24 Filgrastim 24 Whole-Body Irradiation 22 Cisplatin 22 Blood Specimen Collection 22 montanide ISA 51 21 Sorafenib 21

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00612664 2015-10-12

Phase II, 2nd Line Melanoma - RAND Monotherapy

Bristol-Myers Squibb

Phase 2 Completed

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡